๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Auditory Restoration and Outcomes After Gene Therapy and Cochlear Implantation: a PRospective Cohort Analysis (AURORA)
NCT06237790Hearing Loss, Genetic Disease, Speech Perception
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Recruiting
ฮ’-Thalassemia Treatment with KL003 Cell Injection
NCT06280378Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Phase 1/2
41
Shanghai, Tianjin
2024-04-05
Recruiting
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
NCT06127303Non-small Cell Lung Cancer
DrugToripalimab
Shanghai Chest Hospital
Phase 2
54
Shanghai
2024-04-02
Recruiting
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
NCT06341621Breast Cancer
Fudan University
Phase 3
1,900
Shanghai
2024-04-02
Recruiting
Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
NCT06346093Advanced Gastric Cancer
Changhai Hospital
Not applicable
124
Shanghai
2024-04-02
Recruiting
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
NCT06326021Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital
Phase 1
27
Shanghai, Chengdu, Beijing
2024-04-02
Recruiting
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
NCT06307054Relapsed Adult AML, Refractory AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
24
Shanghai
2024-04-01
Recruiting
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
NCT06360133Dry Eye
VivaVision Biotech, Inc
Phase 3
700
Shanghai
2024-04-01
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
NCT06249321Pancreatic Cancer, Radiotherapy
DrugsIMRT·MFOLFIRINOX
Fudan University
Phase 2
30
Shanghai
2024-04-01
Recruiting
Wearable Devices Faciliate the Management of AMI Patients
NCT06995495Acute Myocardial Infarction
RenJi Hospital
Observational
400
Shanghai
2024-04-01
Recruiting
Cohort-Based Study of Diagnostic Biomarkers for Neurosyphilis
NCT06680011Neurosyphilis, Biomarkers, Proteomics
Shanghai Mental Health Center
Observational
360
Shanghai
2024-04-01
Recruiting
Development of Prosocial Behaviors and Related Brain Network in Infants of High and Low Risk of ASD
NCT06329245Autism or Autistic Traits, Healthy
Children's Hospital of Fudan University
Observational
100
Shanghai
2024-04-01
Active, closed
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
NCT06913699Non-alcoholic Fatty Liver Disease (NAFLD)
Shanghai East Hospital
Observational
6
Shanghai
2024-04-01
Recruiting
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
NCT06462053Early Low Rectal Cancer
DrugsToripalimab·Oxaliplatin·Capecitabine
Fudan University
Phase 2
134
Shanghai
2024-04-01
Not yet open
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
NCT06301386Colon Cancer
DrugsPD-1·Everolimus
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer๏ผšChase
NCT07555678Anal Squamous Cell Cancer
Fudan University
Phase 2
241
Shanghai
2024-04-01
Recruiting
Effect of Belimumab on Antibody Titers in Primary APS Patients
NCT06747312Antiphospholipid Syndrome (APS)
Ruijin Hospital
Phase 2
20
Shanghai
2024-04-01
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710Lung Cancer Metastatic, Surgical Resection
Fudan University
Observational
66
Shanghai
2024-04-01
Not yet open
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
NCT06332950Extensive-stage Small-cell Lung Cancer
Baohui Han
Phase 1/2
80
Shanghai
2024-04-01
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
NCT06325527Alzheimer Disease, Neurodegenerative Diseases, Cognitive Impairment, Mild Cognitive Impairment
Ruijin Hospital
Observational
1,872
Shanghai
2024-04-01
Active, closed
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
NCT06305143Diabetic Macular Edema
DrugConbercept
Shanghai Eye Disease Prevention and Treatment Center
Phase 4
58
Shanghai
2024-04-01
Recruiting
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
NCT06256237Limited Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
30
Shanghai
2024-04-01
Recruiting
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT06525428Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
96
Shanghai
2024-04-01
Not yet open
Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
NCT06375616Sepsis
Shen Lei
Phase 4
156
Shanghai
2024-04
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Recruiting
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
NCT06305663Myopia
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Recruiting
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
NCT06335693Prostate Cancer
Changhai Hospital
Not applicable
9
Shanghai
2024-03-28
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
DrugsOxaliplatin·Capecitabine
Fudan University
Phase 2
192
Shanghai
2024-03-28
By invitation
Videodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA
NCT06891079Aortic Stenosis
Xijing Hospital
Not applicable
320
Shanghai, Xi'an
2024-03-28
Active, closed
An Observational Cohort Study to Explore the Clinical Outcome of Congenital Strabismmus Based on Etiology and Timing of Surgery
NCT06614335Congenital Esotropia
Qiyu Bo
Observational
300
Shanghai
2024-03-26
Recruiting
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
NCT06725212Benign Prostatic Hyperplasia
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
NCT06483295Lung Cancer
Shanghai Chest Hospital
Not applicable
216
Shanghai
2024-03-24
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
80
Beijing, Shanghai, Chengdu
2024-03-22
Recruiting
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
NCT06306612Prostate Cancer
RenJi Hospital
Not applicable
192
Shanghai
2024-03-21
Active, closed
A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB
NCT06308120Pulmonary Nodule, Solitary, Lung Cancer
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
RenJi Hospital
Phase 1
30
Shanghai
2024-03-20
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
a Feasibility Study of iHD-SRT for BM
NCT06231186Brain Metastases, Adult, Stereotactic Radiotherapy
Ruijin Hospital
Not applicable
35
Shanghai
2024-03-15
Active, closed
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
NCT05116462Non-Small Cell Lung Cancer
DrugsSintilimab·Nab-paclitaxel·Pemetrexed·Paclitaxel
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Recruiting
The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
NCT07400354Gastric Cancer, Gut Microbiota
Fudan University
Observational
300
Shanghai
2024-03-14
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Recruiting
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
NCT06765564ALS
Shanghai East Hospital
Not applicable
3
Shanghai
2024-03-13
Recruiting
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086HER2-positive Breast Cancer
DrugsDP303c·Trastuzumab emtansine
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
442
Shanghai
2024-03-13
Recruiting
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
NCT06590259Colorectal Cancer Liver Metastasis
DrugsMFOLFOX6·Folfiri·Cetuximab·Sintilimab
Shanghai 6th People's Hospital
Phase 2
20
Shanghai
2024-03-12
Recruiting
IVUS CHIP China Registry
NCT06274645Complex Higher Risk Indicated Patients Undergoing PCI
Shanghai Zhongshan Hospital
Observational
2,020
Shanghai
2024-03-12
Recruiting
Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents
NCT06904079Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder, Paranoid Psychosis
Shanghai Mental Health Center
Not applicable
82
Shanghai
2024-03-12
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·AAA617
Novartis Pharmaceuticals
Phase 3
450
Beijing, Guangzhou, Shanghai
2024-03-12
By invitation
Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema
NCT06232616Epiretinal Membrane
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
20
Shanghai
2024-03-11
Recruiting
Metronomic Capecitabine in Stage III Gastric Cancer
NCT06313567Gastric Cancer
Fudan University
Phase 3
722
Shanghai
2024-03-10
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
NCT06314373Advanced Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Recruiting
An Exploratory Study by Fast CAR T Cells
NCT06327997Solid Tumor
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
20
Shanghai
2024-03-07
Recruiting
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456Non-Small Cell Lung Cancer With EGFR Mutation
DrugTagrisso
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients
NCT06183892Liver Transplant
DrugTacrolimus
RenJi Hospital
Not applicable
80
Shanghai
2024-03-04
Recruiting
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
NCT06314334Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
DrugsGelad·P-Gemox·Pegaspargase·Sintilimab
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Active, closed
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
NCT06228404Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
18
Shanghai
2024-03-03
Recruiting
A-eyedrops on Ocular Alignment and Binocular Vision
NCT05379855Exotropia, Exophoria, Myopia
DrugAtropine eye
Eye & ENT Hospital of Fudan University
Not applicable
339
Shanghai
2024-03-02
Recruiting
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
NCT06196788Pancreatic Cancer
DrugsNab-paclitaxel·Gemcitabine
Fudan University
Phase 2
30
Shanghai
2024-03-01
Recruiting
STICH3C Cardiac Magnetic Resonance Observational Study
NCT07133984Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Weill Medical College of Cornell University
Observational
230
Shanghai
2024-03-01
Active, closed
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
NCT06308393Healthy, Psoriatic Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
98
Hefei, Shanghai
2024-03-01
Active, closed
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
NCT06199973Advanced Colorectal Cancer
DrugTrastuzumab Rezetecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
130
Shanghai
2024-03-01
Active, closed
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
NCT06294678Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1๏ผŒChemotherapy and Target Therapy for Metastatic Colorectal Cancer
NCT06841159Microsatellite Stable Metastatic Colorectal Cancer
DrugSintilimab
Fudan University
Phase 2
116
Shanghai
2024-03-01
By invitation
Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses
NCT06221592Myopia, Progressive
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
252
Shanghai
2024-03-01
Recruiting
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
NCT06255210Olfactory Neuroblastoma
DrugsEtoposide·Cyclophosphamide·Gemcitabine·Cisplatin
Hongmeng Yu
Phase 2
25
Shanghai
2024-03-01
Recruiting
Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage
NCT06715878Kidney Neoplasms
RenJi Hospital
Not applicable
80
Shanghai
2024-03-01
Recruiting
HUC-MSC for Treatment of High-risk HPV Infection
NCT06610773Human Papillomavirus Viruses, Mesenchymal Stem Cells
Shanghai East Hospital
Phase 1/2
60
Shanghai
2024-03-01
Recruiting
Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults
NCT05727722Acute-On-Chronic Liver Failure, Chronic Liver Failure
RenJi Hospital
Phase 1
10
Shanghai
2024-03-01
Recruiting
Delirium Phenotypes and Subsequent Impairment During Transition From ICU to Hospital Wards
NCT07193797Delirium, Post ICU Syndrome
Shanghai Zhongshan Hospital
Observational
189
Shanghai
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
fMRI for BPS: A Descriptive Study of Findings and Symptoms
NCT06294951Bladder Pain Syndrome
RenJi Hospital
Observational
120
Shanghai
2024-03-01
By invitation
Intervention and Effect of Sleep Pattern on Cardio-cerebrovascular Disease
NCT06294964Cardiovascular Diseases, Non-Communicable Chronic Diseases
RenJi Hospital
Not applicable
12,800
Shanghai
2024-03-01
Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963MALT Lymphoma of Stomach, Helicobacter Pylori Infection
Fudan University
Phase 2
160
Shanghai
2024-03
Recruiting
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
NCT06231381Generalized Pustular Psoriasis (GPP)
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2
33
Beijing, Shanghai
2024-02-29
Recruiting
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
NCT07236203Large B-Cell Lymphoma
DrugCar-T
Fudan University
Observational
80
Shanghai
2024-02-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405Respiratory Synctial Virus Infections
DrugZiresovir
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Sanya, Shanghai, Shenyang
2024-02-29
Recruiting
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05935215Atypical Hemolytic Uremic Syndrome
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
50
Nanjing, Beijing, Shanghai
2024-02-28
Recruiting
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364Triple Negative Breast Cancer
DrugsEribulin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
524
Shanghai
2024-02-28
Recruiting
A Study of HC006 in Subjects With Advanced Solid Tumors
NCT06304571Advanced Solid Tumor
DrugHC006
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai
2024-02-27
Recruiting
Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
NCT06207552Fabry Disease
Children's Hospital of Fudan University
Phase EARLY_PHASE1
6
Shanghai
2024-02-20
Recruiting
Neoadjuvant Immunochemotherapy for LAOSCC
NCT06258811Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Lai-ping Zhong
Phase 3
134
Shanghai
2024-02-20
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Recruiting
Early Detection and Post-operative Monitoring of Gastric Cancer
NCT06232395Gastric Cancer
Suzhou Huhu Health & Technology Inc.
Observational
1,197
Shanghai
2024-02-18
Recruiting
Post-operative Monitoring of Gastric Cancer
NCT07026240Gastric Cancer
Suzhou Huhu Health & Technology Inc.
Observational
258
Shanghai
2024-02-18
Recruiting
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
NCT06304350Esophageal Cancer
Tongji University
Phase 2
25
Shanghai
2024-02-17
Not yet open
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
NCT06255795Extranodal Natural Killer T Cell Lymphoma
Ruijin Hospital
Phase 3
142
Shanghai
2024-02-15
Recruiting
Carotid Atherosclerosis in Predicting Coronary Artery Disease
NCT06253962Carotid Atherosclerosis, Coronary Atheroscleroses
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2024-02-10
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Cisplatin·Carboplatin
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Active, closed
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT06198751Breast Cancer
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Not yet open
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
NCT06217042Pancreatic Cancer
DrugsHR070803·5Fluorouracil·Calcium folinate·Oxaliplatin
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
Pegylated Interferon ฮฑ in Previously Interferon-treated CHB๏ผˆLeading Study๏ผ‰
NCT06323681Chronic Hepatitis b
Qing XIe
Not applicable
2,016
Shanghai
2024-02-04
Recruiting
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354Safety, Tolerability, Efficacy
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Recruiting
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NCT06329999Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia
Ruijin Hospital
Not applicable
78
Shanghai
2024-02-03
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860Lung Cancer
DrugsDisitamab Vedotin·Tislelizumab·Bevacizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
NCT06256224Cervical Cancer, Chemoradiotherapy, Immunotherapy
DrugToripalimab
Ruijin Hospital
Not applicable
150
Shanghai
2024-02-02
Rows per page Showing 2601–2700 of 3827
Previous 25 26 27 28 29 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=27

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.